Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Ibrutinib therapy in mantle cell lymphoma (MCL)

Simon Rule • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Ibrutinib

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent studies of the Bruton’s tyrosine kinase inhibitor, ibrutinib, in mantle cell lymphoma (MCL), including in patients with relapsed or refractory MCL who progress after bortezomib therapy and mutational analysis of these patients with primary resistance to ibrutinib, and ibrutinib in combination with rituximab.

More from Simon Rule

Real-world results in the UK for ibrutinib at first relapsed for MCL
0:48
Real-world results in the UK for ibrutinib at first relapsed for MCL
Simon Rule • 7 Dec 2019
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
1:30
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
Simon Rule • 7 Dec 2019
Impressive results for R-BAC post BTKi in R/R MCL
1:28
Impressive results for R-BAC post BTKi in R/R MCL
Simon Rule • 7 Dec 2019
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
1:35
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
Simon Rule • 6 Dec 2019

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals